ReviewFrontiers in pharmacology2026
Sex-dependent serotonergic signaling across development: molecular mechanisms shaping vulnerability to neurodevelopmental and mental disorders.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychiatric disorders and several neurodevelopmental conditions, including autism spectrum disorder, display marked sex biases in prevalence, symptom profiles, and treatment response. Converging evidence has positioned the serotonergic system as a key organizer of the brain during development and across the lifespan; however, the principles determining when serotonin acts permissively or instructively remains unresolved. In this Review, we critically examine interventional studies across sensitive developmental and adult windows to assess whether serotonergic signaling acts in a sex-dependent manner to shape circuit architecture and bias vulnerability to neurodevelopmental and psychiatric disorders. We argue that the consequences of serotonergic perturbation depend on developmental timing, biological sex, hormonal context, and circuit identity, rather than solely on serotonin levels. Finally, we discuss how staged interactions among serotonergic signaling, endocrine state, and circuit phenotypes-potentially modulated by RNA-centered regulatory processes-may offer a mechanistically plausible framework through which transient environmental challenges acquire lasting effects on neurodevelopmental and affective vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.